MHC class I antigens in malignant cells : immune escape and response to immunotherapy / / Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera

• Record Nr.: UNINA9910437613903321
• Autore: Aptsiauri Natalia
• Pubbl/distr/stampa: New York, : Springer, c2013
• ISBN: 1-4614-6543-5
• Edizione: [1st ed. 2013.]
• Descrizione fisica: 1 online resource (51 p.)
• Collana: SpringerBriefs in cancer research ; ; 6
• Altri autori (Persone): Garcia-LoraAngel Miguel; CabreraTeresa
• Disciplina: 616.99/4079
• Soggetti: Oncology; Immunology
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di contenuto: Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
• Sommario/riassunto: Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a ; tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. .